Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 November 2022 | Story André Damons

The Department of Pharmacology at the University of the Free State (UFS), together with the Technology Innovation Agency (TIA), is hosting the first Indigenous Knowledge and Bio-Trade Indaba on the Bloemfontein Campus. The Department of Science and Innovation (DSI) and TIA are the sponsors of the event. 

Prof Motlalepula Matsabisa, Professor and Director of Pharmacology, will play host to the various stakeholders to network and share knowledge on current developments in indigenous knowledge research and product development, biodiversity, innovation, and commercialisation of the IK-based research products. The Indigenous Knowledge System (IKS) for Health unit in the Department of Pharmacology within the UFS Faculty of Health Sciences was last year awarded an annual Technology Innovation Agency Platform (TIA) grant of R17 million for the next five years.

The research and teaching programme in the School of Clinical Medicine has since been rebranded and is now known as the African Medicines Innovation and Technology Development Platform (AMITD), which will strive to respond to community health needs and address industry research needs and challenges.

The indaba will showcase progress made by TIA and other entities in enriching the development and commercialisation of IK-based innovations. It will take place from 24 to 25 November 2022 in the Equitas Senate Hall at the UFS. 

Prof Matsabisa is the chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19. He is also a visiting professor at the Beijing University of Chinese Medicine (BUCM) in Beijing, China, and the Deputy President of the South African Society for Basic and Clinical Pharmacology.
 

News Archive

Martie Miranda one of only 10 SATI accredited sign language interpreters in South Africa
2015-04-23

Martie Miranda
Photo: Stefan Lotter

The University of the Free State is privileged to have one of the top South African Sign Language (SASL) Interpreters as a staff member at the Unit for Students with Disabilities (USD).

Martie Miranda recently passed the accreditation exam of the South African Translators Institute (SATI), joining Dr Philemon Akach, previous HOD of the South African Sign Language Department of the UFS, in becoming one of only 10 SASL interpreters to be SATI accredited.

SATI is a professional association for language practice professionals in South Africa. Voluntary accreditation is offered at a professional level, ensuring a high standard of language practice. The system has become widely recognised, and is used as a recommendation or prerequisite for job applications by a number of institutions, including the South African government, particularly after the infamous ‘Jantjies incident’ with the funeral service of the late President Nelson Mandela.

Martie, a proud Child of Deaf Adults (CODA), has 18 years’ experience in SASL interpreting, lip speaking interpreting, and community interpreting as well as 15 years’ experience of conference and seminar interpreting. She boasts a Level 2 Advanced Interpreting qualification, and she has been mentoring Level 1 SASL interpreters for the past six years. Her extensive interpreting experience on a national and international level also includes Deafblind interpreting as well as Court and Legislature interpreting. She has interpreted three theatre productions, and has been coordinating the SASL services at the UFS since January 2009. She is responsible for the student management of all the hearing-impaired students at the USD.

Martie completed her BML degree (cum laude) at the UFS Business School in 2013, and received the award for top achiever in the programme during her final year. She will enrol for her MBA at the UFS Business School in July 2015.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept